Small molecule compound for treating optic neuromyelitis and high-throughput screening method thereof

Abstract

The invention provides a small molecule compound high-throughput screening method for treating optic neuromyelitis and provides a small molecule compound used for treating the optic neuromyelitis andcapable of blocking a series of inflammation reaction induced by binding of NMO-IgG to AQP4 on the surfaces of astrocyte membranes. The method is scientific, reasonable and high in adaptability. The small molecule compound is safe, reliable and good in treatment effect. The chemical structural formulas are respectively shown as follows.

Description

technical field [0001] The invention belongs to the fields of biology and pharmacy, in particular, it relates to a small molecular compound for treating neuromyelitis optica and a high-throughput screening method thereof. Background technique [0002] Neuromyelitis optica (NMO) is a selective inflammatory demyelinating disease of the central nervous system involving the optic nerve and spinal cord. Clinically, the main feature is simultaneous or sequential involvement of the optic nerve and spinal cord, showing a progressive or alternating course of remission and relapse. The disease was first described by Devic (1894), also known as Devic's disease. In the past, NMO was considered to be a subtype of multiple sclerosis, but with the discovery of aquaporin AQP4 (aquaporin4, AQP4) autoantibodies, NMO is independent of The autoimmune channelopathy of multiple sclerosis has its own pathogenesis and clinical features. Epidemiological data show that the prevalence of NMO is abou...

AI Technical Summary

Problems solved by technology

Traditional glucocorticoid therapy is mainly aimed at the inflammatory response in the acute relapse stage, but it is ineffective in controlling the progression of the disease and reducing neurological damage. Glucocorticoids have a negative impact on the survival of retinal optic ganglion cells, and the side effects of long-term glucocorticoid therapy are relatively low. Many, so limit its use

Antimetabolic immunosuppressants such as azathioprine also have many adverse reactions, including blood system reactions (such as anemia, leukopenia, thrombocytopenia, etc.), digestive system reactions (such as nausea, vomiting and other gastrointestinal symptoms), occasionally Toxic hepatitis, pancreatitis, and suppression of the reproductive system, long-term use will also increase the chance of tumor occurrence

Plasma exchange can be carried out in qualified medical departments to remove autoantibodies, antigen-antibody complexes, cytokines, and other inflammatory harmful substances that cause diseases in patients. Plasma exchange therapy has a certain effect on relieving symptoms in the acute phase. However, it cannot control the recurrence and reduce the degree of neurological deficit. Non-specific exchange will cause the loss of other non-pathogenic components in the plasma. The adverse reactions include anemia, heparin-related thrombocytopenia, and increased chances of infection.

[0005] The above treatment plan is mainly aimed at reducing the amount of NMO-IgG. Although it can alleviate clinical symptoms and control the disease in the short term, it has the disadvantages of poor specificity and large side effects. A series of pathological processes triggered by links

Images